On the basis of these results, single-agent ramucirumab was evaluated in the second-line treatment of HCC patients with an elevated AFP level (≥400 ng/ml) in REACH-2 and was shown to significantly improve OS and PFS. This evidence concerns the gene AFP and hepatocellular carcinoma.